StockData

Keros Therapeutics vs vTv Therapeutics

KROS and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KROS and VTVT compare

Keros Therapeutics is the larger company, worth 3.3 times as much as vTv Therapeutics ($224M against $68.4M).

vTv Therapeutics grew revenue faster over the last twelve months (216600% versus −93.7% for Keros Therapeutics).

vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −12.9% compared with −572% at Keros Therapeutics.

vTv Therapeutics scores higher on the StockData Score (11 against 7 for Keros Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKROSVTVT
Size and price
Market cap$224M$68.4M
Share price$11.31$17.29
Change, 1 year−34.5%−43.9%
Change, 5 years−79.8%−67.7%
Beta (5Y)2.040.08
Employees7826
StockData Score
Total score711 (better)
Valuation score13 (better)
Growth score01 (better)
Performance score12 (better)
Health score55
Dividend score00
Valuation
P/S15.4×1.9× (better)
P/B0.9× (better)0.9×
FCF yield−21.6%–
Fair value–$44.97
Margin of safety–61.6%
Growth
Revenue growth (TTM)−93.7%216600% (better)
Net income growth (TTM)−543%–
EPS growth (TTM)−1287%–
Profitability
Operating margin−698%−25.1% (better)
Net margin−572%−12.9% (better)
FCF margin−334%–
Return on equity−17.2%−11.7% (better)
Return on invested capital−755%–
Financial health
Debt / equity0.000.00
Current ratio21.96 (better)12.48
Altman Z-score2.67 (better)0.71
Piotroski F-score6 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions101%40.6%
Held by insiders53.3%26.3%
Insider net buying, 12 months−$453K–
Short interest, % of float11.7%5.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.